Senses Disorder TRIZ Cases

Modified bridged piperazinyl alkanone structures reduce hERG inhibition and metabolization while maintaining potent p75NTR binding activity.

Antibody EXO 6A10 inhibits carbonic anhydrase XII forty times better than azetazolamide, reducing tumor growth under hypoxia.

Assembly activating protein drives VP3 parvovirus particle formation using rep-independent promoters, resolving DNA contamination issues in vaccine production.

Compounds antagonizing NLRP1 and NLRP3 activity inhibit IL-10 and IL-18 production, addressing inadequate treatment options.

Novel pyrazine derivatives inhibit SHP2 enzymatic activity through targeted catalytic site binding.

Formula A compounds inhibit FLAP activity, reducing leukotriene synthesis while minimizing side effects from existing treatments.

Kinase inhibitor coated intraocular lenses inhibit lens epithelial cell migration during cataract surgery.

Modular substituted aminothiazoles inhibit DGKζ to boost T cell immunity, addressing insufficient anti-tumor efficacy in current treatments.

Nanostructured wafer with mucoadhesive polymer anchors in conjunctival cul-de-sac for controlled drug diffusion.

Monoclinic cyclosporine A Form 2 resolves stability and solubility contradictions to improve ocular drug delivery efficacy.

Direct precipitation of cerium oxide nanoparticles using citric acid and EDTA stabilizes dispersion and boosts catalase-like activity without toxic surfactants.

Plasmalogen precursors bypass peroxisomal pathways to mobilize membrane cholesterol for storage, resolving statin limitations.

Cannabidiol acts as an intermediary to reduce metabolic and extrapyramidal side effects of aripiprazole in psychosis treatment.

2,5-disubstituted benzoxazole derivatives inhibit NADPH oxidase 4 to manage oxidative stress and fibrosis in pulmonary and systemic diseases.

A herbal composition using avocado, ecklonia cava, and perilla extracts reduces nitric oxide secretion to treat hearing impairment.

N-terminal modifications of thymosin beta 4 create Gly-Tbeta4 and Ala-Tbeta4 derivatives that accelerate heart and skin lesion healing while reducing fibrosis.

Pyridopyrazine derivatives resolve low solubility and metabolic stability issues in conventional quinoxaline-based inhibitors.

Cafestol addresses insulin resistance by boosting insulin secretion and enhancing glucose uptake to manage type 2 diabetes.

Quinazolyl amine compounds block RIP2 kinase activity to resolve the trade-off between therapeutic effectiveness and selective inhibition.

Spiro-heterocyclic structures resolve contradictions between drug reliability and side effects while inhibiting amyloid beta deposition.

Suspended RPL554 particles with controlled size distribution prevent degradation during storage while enabling delayed drug release.

Segmented polymer layers control diffusion rates to maintain therapeutic concentrations, reducing intraocular pressure without frequent re-application.

Tranilast analogues treat diabetic retinopathy by inhibiting inflammatory and angiogenic processes without damaging healthy retina tissue.

A heterocyclic compound of formula I inhibits dual leucine zipper kinase activity to prevent neuronal damage.

Azaindole derivatives with specific cycloalkenyl groups selectively inhibit JAK3, resolving side effects from non-specific JAK1 and JAK2 inhibition.

An ophthalmic solution containing UV-A and UV-B absorbers filters harmful radiation.

Parthenogenetic activation of human oocytes overcomes ethical concerns and low success rates to produce autologous stem cells.

Plasma enhanced chemical vapor deposition coatings on plastic syringe walls prevent sterilization gas penetration and maintain drug stability.

Segmented nanoparticulate corticosteroids evade rapid mucociliary clearance, extending nasal residence time and accelerating therapeutic onset.

Taurine replaces alkali metal chlorides in polyacrylic acid formulations to increase solution viscosity and extend adhesion time on the eye surface.

Segmented differentiation and feedback control generate high-purity keratinocyte stem cells with long-term proliferative capacity for transplantation.

Composite extract removes deposited materials to regenerate Bruch's membrane, resolving nutrient deficiency and metal deposition damage.

Isotopic substitution shifts metabolism away from aldehyde oxidase pathways, reducing insoluble metabolite formation and renal toxicity in c-Met inhibitors.

Optimized 26-30 nucleotide duplexes enhance potency and duration while avoiding interferon responses.

A cyclosporin A emulsion delivers therapeutic drug concentrations to ocular tissue.

Combines PGE2 compounds with myotoxins to stimulate muscle stem cells.

Small activating RNAs target sense mRNA transcripts to up-regulate specific gene expression without requiring prior antisense transcript identification.

An alkyl ether derivative binds to the emopamil binding protein with high affinity.

Novel FXR modulating compounds bind to the NR1H4 receptor to improve bile acid metabolism while reducing inflammatory responses in metabolic disorders.

A subconjunctival hydrogel reservoir releases silibinin through the sclera to sustain retinal concentrations.

Chemical modifications enable dose-dependent TLR9 antagonism, resolving excessive immune activation or inhibition.

Optimized molecular weight enables low-molecular weight carboxamide porphyrins to diffuse through biological barriers while maintaining strong light absorption.

Lipid carriers deliver double stranded RNA to silence transthyretin expression and reduce amyloid deposits.

A biologically active polypeptide conjugated to a biocompatible polymer extends drug residence time in the vitreous.

Combining mu-opioid receptor antagonists with mTOR inhibitors enables lower dosing to reduce adverse reactions while maintaining therapeutic effectiveness.

Deuterated anthraquinone compounds convert into cytotoxic forms within tumor cells under hypoxic conditions.

Macrolactonization achieves high cis-selectivity, eliminating costly HPLC purification for mass production.